Cristina Saura
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Nuciforo P, Townend J, Piccart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia A, Gomez H, Gombos A, Coccia-Portugal M, Tseng L, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer 2022; 181:92-101.
27.12.2022Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
27.12.2022Eur J Cancer 2022; 181:92-101
Nuciforo Paolo, Townend John, Piccart Martine, Fielding Shona, Gkolfi Panagiota, El-Abed Sarra, de Azambuja Evandro, Werutsky Gustavo, Bliss Judith, Moebus Volker, Colleoni Marco, Aspitia Alvaro Moreno, Gomez Henry, Gombos Andrea, Coccia-Portugal Maria Antonia, Tseng Ling-Ming, Kunz Georg, Lerzo Guillermo, Sohn Joohyuk, Semiglazov Vladimir, Saura Cristina, Kroep Judith, Ferro Antonella, Cameron David, Gelber Richard D, Huober Jens, Di Cosimo Serena
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
Chumsri S, Holmes E, Di Cosimo S, Werner O, Huober J, Dueck A, Sotiriou C, Saura C, Moreno-Aspitia A, Knutson K, Perez E, Van Dooren V, Hilbers F, Carey L, Li Z, Serie D, Norton N, Mashadi-Hossein A, Tenner K, Brauer H, Warren S, Danaher P, Colon-Otero G, Partridge A, Thompson E. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer 2022; 8:68.
24.05.2022Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
24.05.2022NPJ Breast Cancer 2022; 8:68
Chumsri Saranya, Holmes Eileen, Di Cosimo Serena, Werner Olena, Huober Jens, Dueck Amylou C, Sotiriou Christos, Saura Cristina, Moreno-Aspitia Alvaro, Knutson Keith L, Perez Edith A, Van Dooren Veerle, Hilbers Florentine, Carey Lisa A, Li Zhuo, Serie Daniel J, Norton Nadine, Mashadi-Hossein Afshin, Tenner Kathleen, Brauer Heather Ann, Warren Sarah, Danaher Patrick, Colon-Otero Gerardo, Partridge Ann H, Thompson E Aubrey
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
van Rees D, Saura C, Di Cosimo S, Huober J, Roylance R, Kim S, Kuijpers T, van Bruggen R, K van den Berg T, Guillaume S, Izquierdo M, El-Abed S, Bouti P, Klein B, Verkuijlen P, van Houdt M, Schornagel K, Tool A, Venet D, Sotiriou C, Matlung H. Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. J Immunother Cancer 2022; 10
01.01.2022Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
01.01.2022J Immunother Cancer 2022; 10
van Rees Dieke J, Saura Cristina, Di Cosimo Serena, Huober Jens, Roylance Rebecca, Kim Sung-Bae, Kuijpers Taco W, van Bruggen Robin, K van den Berg Timo, Guillaume Sébastien, Izquierdo Miguel, El-Abed Sarra, Bouti Panagiota, Klein Bart, Verkuijlen Paul J H, van Houdt Michel, Schornagel Karin, Tool Anton T J, Venet David, Sotiriou Christos, Matlung Hanke L
Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
Venet D, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Saura C, Wang Y, Rediti M, Maetens M, Fumagalli D, Brown D, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. Clin Cancer Res 2021
28.07.2021Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
28.07.2021Clin Cancer Res 2021
Venet David, Gomez Henry, Semiglazov Vladimir, de Azambuja Evandro, Huober Jens, Nuciforo Paolo, Di Cosimo Serena, Piccart-Gebhart Martine, Loi Sherene, Rothé Françoise, Saura Cristina, Wang Yingbo, Rediti Mattia, Maetens Marion, Fumagalli Debora, Brown David N, Majjaj Samira, Salgado Roberto, Pusztai Lajos, Harbeck Nadia, El-Abed Sarra, Sotiriou Christos
Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Chic N, Prat A, Huober J, Saura C, Di Cosimo S, Láng I, de Azambuja E, Wang Y, Hilbers F, Fumagalli D, Salgado R, Nuciforo P, Luen S, Loi S. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. J Natl Cancer Inst 2021
31.03.2021Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
31.03.2021J Natl Cancer Inst 2021
Chic Nuria, Prat Aleix, Huober Jens, Saura Cristina, Di Cosimo Serena, Láng István, de Azambuja Evandro, Wang Yingbo, Hilbers Florentine, Fumagalli Debora, Salgado Roberto, Nuciforo Paolo, Luen Stephen J, Loi Sherene
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Di Cosimo S, Daidone M, Piccart M, Izquierdo M, Fumagalli D, Huober J, Saura C, De Santis M, Franzoi M, Cinieri S, Agbor-Tarh D, Porcu L, de Azambuja E. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res 2020; 22:115.
27.10.2020Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
27.10.2020Breast Cancer Res 2020; 22:115
Di Cosimo Serena, Daidone Maria Grazia, Piccart Martine, Izquierdo Miguel, Fumagalli Debora, Huober Jens, Saura Cristina, De Santis Maria Carmen, Franzoi Maria Alice, Cinieri Saverio, Agbor-Tarh Dominique, Porcu Luca, de Azambuja Evandro